VHT vs. XBI: Is Diversified Healthcare Exposure or Biotech Stocks the Smarter Choice for Investors?

Katie Brockman, The Motley Fool

Tue, September 22, 2026 at 11:01 PM GMT+3 4 min read

The Vanguard Health Care ETF (NYSEMKT:VHT) offers broad sector exposure and lower fees, while the State Street SPDR S&P Biotech ETF (NYSEMKT:XBI) provides a concentrated, more volatile play on the biotechnology subsector.

Investors looking for exposure to the medical field often weigh broad sector coverage against niche industry plays. This comparison examines how a diversified giant like VHT stacks up against a more volatile, subsector-focused option like XBI, highlighting differences in risk, cost, and portfolio concentration.

Snapshot (cost & size)

Beta measures price volatility relative to the S&P 500; beta is calculated from monthly returns over the available fund history (up to five years). The 1-yr return represents total return over the trailing 12 months. Dividend yield is the trailing-12-month distribution yield.

Cost-conscious investors may find VHT more appealing, as its 0.09% expense ratio is significantly lower than XBI's 0.35%. Furthermore, the Vanguard fund provides a more substantial income stream with a 1.48% dividend yield, compared to the 0.35% offered by its biotech-focused peer.

Performance & risk comparison

What's inside

VHT provides broad exposure to the U.S. healthcare sector, holding 416 stocks through a passive replication strategy. Its portfolio is 100% focused on healthcare companies, and its largest positions include Eli Lilly, Johnson & Johnson, and AbbVie. The fund was launched in 2004 and has paid $4.72 per share in dividends over the trailing 12 months.

XBI focuses specifically on the biotechnology industry, tracking its index through representative sampling. This approach results in a more concentrated portfolio of 165 holdings, with the largest positions in Twist Bioscience, Moderna, and Natera. The fund was launched in 2006 and has paid $0.57 per share in dividends over the trailing 12 months.

For more guidance on ETF investing, check out the full guide at this link.

Which looks like the better buy

VHT and XBI differ in their scope and diversification, which have had meaningful impacts on their risk profiles and performance.

VHT is the more diversified of the two, not just in terms of the number of stocks, but in its sector focus, too. Around 24% of the fund is allocated to biotechnology stocks, but it also provides exposure to pharmaceuticals, healthcare equipment, life sciences, and more.

XBI's more targeted approach has led to a substantially higher one-year total return, more than doubling VHT's performance. However, it's also experienced a much more severe max drawdown and a higher beta, suggesting greater short-term volatility.

Choosing between them will depend on the gaps you're looking to fill within your portfolio. XBI can provide targeted exposure specifically to biotechnology stocks as part of a well-diversified portfolio, while VHT offers broader access to the greater healthcare sector. Both ETFs can be smart choices, but the right one will depend on your unique situation.

Should you buy stock in Vanguard World Fund - Vanguard Health Care ETF right now?

Before you buy stock in Vanguard World Fund - Vanguard Health Care ETF, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Vanguard World Fund - Vanguard Health Care ETF wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $395,625!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,397,147!*

Now, it's worth noting Stock Advisor's total average return is 951% — a market-crushing outperformance compared to 214% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.

See the 10 stocks »

*Stock Advisor returns as of September 22, 2026.

Katie Brockman has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends AbbVie, Eli Lilly, Moderna, Natera, and Twist Bioscience. The Motley Fool recommends Johnson & Johnson and SPDR Series Trust - SPDR S&P Biotech ETF. The Motley Fool has a disclosure policy.

VHT vs. XBI: Is Diversified Healthcare Exposure or Biotech Stocks the Smarter Choice for Investors? was originally published by The Motley Fool